Joseph P. Menetski, Ph.D., Associate Vice President of Research Partnerships

Joseph Menetski is Director of the Biomarkers Consortium. He received his Ph.D. from Northwestern University Medical School with Dr. Stephen Kowalczykowski and completed his post-doctoral training at the Laboratory of Molecular Biology, National Institutes of Health (NIH/NIDDK) with Dr. Martin Gellert. He then started his career in industry in 1993 in the Immunopathology Department at Parke-Davis (later Pfizer), where he established a discovery research program in cellular inflammation that eventually transitioned to the molecular study of osteoarthritis. Joseph moved to Merck in 2004. His first position was in the department of Immunology where he was involved in the osteoarthritis new targets and biomarker program. While at Merck he has been a member of the Molecular Profiling group, the Knowledge Discovery and Knowledge Management group and finally a Director in Global Competitive Intelligence.

  Stacey J. Adam, Ph.D., Director, Cancer

Dr. Stacey Adam is the Scientific Program Manager for Cancer at the FNIH. In her role, she leads the Cancer Research Partnership programs. She is a molecular pharmacologist/cancer biologist skilled in molecular biology techniques, animal modeling, clinical genomics, systems biology, project and team management and strategy consulting.


Prior to FNIH, Dr. Adam was a Manager at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy practice where she supported a number of federal and not-for-profit client projects. She was the project manager and scientific research advisor for an institute-wide research strategic planning effort at the NIH and for a project to develop a novel technology platform to assist a major non-profit agency with combining clinical, genomic and patient-generated data to accelerate research on chronic gastrointestinal diseases. She also worked for two years with a federally-associated not-for-profit granting agency as a scientific review officer.


Before Deloitte, Dr. Adam conducted her postdoctoral fellowship at Stanford University School of Medicine, Department of Oncology where she was an NIH and American Cancer Society supported fellow. While at Stanford, she focused on developing better animal models for studying lymphoma and osteosarcoma; performing large cancer genomics screens for genes related to self-renewal, differentiation, and tumor recurrence; merging high-throughput biological techniques with novel cancer animal models to define molecular disease signatures to allow for rapid diagnosis and prognosis of cancer; and working with companies to test novel compounds in pre-clinical trials.

  Eline Appelmans, M.D., MPH, BMedSci, Scientific Program Manager, Neuroscience

Dr. Eline Appelmans is a Scientific Program Manager for Neuroscience at the Foundation for the National Institutes of Health. In her role, Dr. Appelmans leads the Neuroscience portfolio and team. She works in coordination with the NIH, non-profit, industry leaders, and FNIH project leads on the implementation of the Accelerating Medicines Partnership (AMP) for Alzheimer’s Disease (AMP-AD), AMP Parkinson’s Disease (AMP-PD), Disease Neuroimaging Initiative 3 Private Partner Scientific Board (ADNI3 PPSB) and the Biomarkers Consortium Neuroscience Steering Committee (BC NSC), and other projects in development. Directly managing AMP-AD and AMP-PD.


Prior to joining the FNIH team, Dr. Appelmans worked for 3.5 years at Fred Hutchinson Cancer Research Center in Seattle WA, specializing in biostatistics, bioinformatics, and epidemiology related to Vaccine and Infectious Diseases. Dr. Appelmans also spent time working at Beaumont Hospital Ireland in Colorectal and General Surgery as well as Gynecology, Urology, Infectious Diseases, and Stroke, and Geriatric Medicine. Dr. Appelmans received her Master’s in Public Health from University of Washington and her Medical Degree and associated Bachelors in Medical Science from the Royal College of Surgeons in Ireland.

  Dana Connors, M.S., P.M.P., Senior Project Manager, Cancer

Dana E. Connors is a Scientific Project Manager for Cancer projects within the Biomarkers Consortium at FNIH. He was most recently a Project Manager for the Electronic Data Methods Forum at AcademyHealth and has extensive experience as an independent consultant working internationally with health care companies and device manufacturers in marketing, communications and project management. In addition to strategic planning, branding and product development assistance, his projects included seminar and symposia planning and collaboration on research project design and clinical trial development. Before his consulting role, Dana worked in marketing and communications management for the biomarker portfolios of Thermo Fisher Scientific and BRAHMS Diagnostics. Dana received his Master of Science from the University of Amsterdam in 2006 and a Bachelor of Arts from the University of Florida..

  Stephanie Cush, Ph.D., Senior Project Manager, Inflammation & Immunity

Dr. Stephanie Cush is the Scientific Project Manager for Inflammation and Immunity at the Foundation for the National Institutes of Health. She manages established and emerging projects within the Biomarkers Consortium Inflammation and Immunity Steering Committee and supports the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Program.


Dr. Cush is trained in cellular immunology and molecular biology with focus areas in T cell immunology, infectious diseases, and immune modulation. In her current role, she utilizes her skills in strategic planning and consulting, project and program management, and building multi-stakeholder alliances.


Prior to FNIH, Stephanie was a Senior Strategy Consultant at Deloitte Consulting within the Federal Life Sciences and Healthcare Strategy practice where she served on a number of federal health projects. She was the project coordinator supporting the NIH in its strategic vaccine development efforts for an emerging viral epidemic. She also worked for 2 years at the Center for Drug Evaluation and Research at the FDA to design, develop and implement an enterprise-wide technology solution to streamline the drug approval process.


Before Deloitte, Dr. Cush conducted her post-doctoral training in the Laboratory of Viral Diseases at the National Institute of Allergy and Infectious Diseases at NIH, studying the immune response and host-pathogen interactions at the site of infection using in vivo imaging techniques. She earned her Ph.D. in Integrated Biomedical Sciences with a focus in Immunology from the Ohio State University, and a B.A. in Microbiology and Molecular Biology from Miami University.

  Helen Heymann, MMSC, Scientific Project Manager, Metabolic Disorders

Helen Heymann is the Scientific Project Manager for Metabolic Disorders within the Biomarkers Consortium at the Foundation for the National Institutes of Health (FNIH).


Helen worked most recently in the health membership association where she was the Senior Program Manager for Education overseeing the education and awards portfolio in collaboration with multiple committees. Prior to this, Helen served for several years as a Senior Health Project Manager at Family Health International 360, a non-profit, where she designed strategic plans and managed national and international health and nutrition projects with partners to address health disparities through evidence-based practices. Helen also worked at the United National Development Program Headquarters and at a Country Office in various program capacities ranging from project and grants management to quality control and communications.


Helen earned a Masters of Science in Health/Social Policy & Planning from the London School of Economics and Political Science and a Masters of Medical Sciences in Human Nutrition from the University of Sheffield.

  Steve Hoffmann, M.S., Director, Inflammation & Immunity

Steve Hoffmann is the Director, Inflammation and Immunity in Research Partnerships at the Foundation for the National Institutes of Health (FNIH). In this role, he provides strategic planning, programmatic management and research administration of a broad portfolio of established and emerging projects in arthritis, organ toxicity, infectious disease and other autoimmune and inflammatory diseases.


Steve has worked for over 20 years in the academic, government and industry sectors in the field of translational biomarkers, molecular immunology and precision medicine with a focus on multi-stakeholder partnerships and project development. Prior to joining FNIH, Steve worked as both a project and product manager at Meso Scale Discovery (MSD), a protein diagnostics biotech in Gaithersburg, MD, gaining extensive experience in team management, product development and marketing of multiplex protein immunoassays. Before MSD, Steve was a scientist in the Transplantation and Autoimmunity Branch of the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) and led research efforts utilizing immune depletion and co-stimulatory blockade strategies for human renal and islet cell transplant trials. His work focused on molecular profiling of surrogate biomarkers of rejection, tolerance and drug toxicity. Steve holds a Master of Science degree in Pathology and Laboratory Medicine from the University of North Carolina at Chapel Hill and a Bachelor of Science degree in Biochemistry and Biophysics from the University of Pittsburgh.

  Wesley Horton, M.S., Scientific Project Manager, Neuroscience

Wesley Horton is a Scientific Project Manager for Neuroscience at the Foundation for the National Institutes of Health. Wesley manages the Biomarker Consortium Neuroscience Steering Committee (BC NSC), the Plasma Aβ Project and various working groups operating under the BC NSC. Prior to joining the FNIH team, Wesley worked for Georgetown University for four years as a Clinical Trial Manager for interventional Alzheimer’s disease studies and developed clinical research programs in Stroke, Neurosurgery, and Interventional Radiology. He also spent time working with the Henry M. Jackson Foundation managing multi-center clinical trials to understand HIV and HIV Associated Neurocognitive Disorder. Mr. Horton received his Master’s in Clinical and Translational Research from Georgetown University with a focus on mechanistic and biomedical research and his Bachelor’s of Science in Psychology from the University of Mary Washington.

  Tania Kamphaus, M.Sc., Ph.D., Scientific Program Manager, Metabolic Disorders

Dr. Tania Nayak Kamphaus is the Scientific Program Manager for Metabolic Disorders at the FNIH. In her role, she leads the Metabolic Disorders Research Partnership programs and manages the Steering Committee for Metabolic Disorders Biomarkers Consortium as well as the Type 2 Diabetes Accelerated Medicines Partnerships (AMP T2D) program in coordination with the NIH, non-profit and industry leaders. Dr. Kamphaus is trained in molecular genetics, molecular and cell biology and skilled in strategic planning and collaborative program development across basic, translational and clinical research.


Prior to joining the FNIH, Dr. Kamphaus was the Director of the Office of Clinical Protocol Development at the University of Wisconsin-Madison, where she supported development of large clinical trial protocols ranging from interventional and observational studies to implementation and dissemination studies. She also served as a key member of the Trial Initiation Network (TIC).


Before her work in clinical trials, Dr. Kamphaus was Director of Collaborative Research at the Crohn’s and Colitis Foundation. In this role, she oversaw nine translational research consortia in Inflammatory Bowel Diseases (IBD), including IBD Genetics and Gut Microbiome, as well as quality of care and patient-centric programs. Dr. Kamphaus was the program director for IBD Plexus, the world’s largest research database for IBD.


Dr. Kamphaus conducted her postdoctoral fellowship at Columbia University at the department of Pathology and Cell Biology. She has published important works in neuronal stem cell migration, standardizing techniques for animal modeling and in vivo imaging. Dr. Kamphaus earned her PhD in Molecular Genetics from The Ohio State University and her Masters in Biotechnology from Madurai Kamaraj University, India.

  Noam Keren, M.A., Scientific Project Manager, Neuroscience

Noam Keren is a Scientific Project Manager for Neuroscience at the Foundation for the National Institutes of Health (FNIH). Noam supports projects focusing on neuropsychiatric disorders under both the Accelerating Medicines Partnership (AMP) and Biomarkers Consortium (BC) programs at FNIH. Prior to joining FNIH, Noam served as a Science Officer for Neuroscience and Mental Health at the Congressionally Directed Medical Research Programs (CDMRP).


Previously, Noam worked for four years as a staff officer at the National Academies of Sciences, Engineering, and Medicine (NASEM), supporting and leading activities in the Health and Medicine Division and the Division of Behavioral and Social Sciences and Education. Noam’s research experience is in cognitive neuroscience, investigating the neurobiology of cognitive performance and neuromodulation in animal models and human populations using behavioral measures and advanced neuroimaging methods. Noam received his master’s degree in psychology from Washington University in St. Louis, and his Bachelor of Science degree from the University of Florida.


  Cheryl Melencio, Executive Assistant

Ms. Melencio provides administrative support to the Director and Scientific Program Managers of The Biomarkers Consortium. In that capacity, she supports the Executive Committee and Steering Committees. Cheryl has been with the FNIH since 2007. Previously she was employed by The National Industrial Transportation League.

  Emily Morgan, Associate Project Manager

Emily Morgan provides administrative assistance to the Research Partnership team. Emily has been with the Foundation since April 2016. Previously she was employed by 0ptimus, a political consulting firm.

  Erin Rosenbaugh, Ph.D., P.M.P., Associate Scientific Project Manager, Neuroscience

Dr. Erin Rosenbaugh is an Associate Scientific Project Manager for Neuroscience at the Foundation for the National Institutes of Health (FNIH). She supports the Plasma Aβ and Alzheimer’s Disease (AD)-Targeted Cerebrospinal Fluid (CSF) Proteomics Projects within the Biomarkers Consortium. Before joining FNIH, Erin was a Scientific Project Manager for Cape Fox Corporation where she recruited and managed multidisciplinary federal contractors for the National Institutes of Health (NIH) Scientific Technical and Other Professional Support Services (STOPS) Program as well as launched operations for the National Institute of Allergy and Infectious Disease NIAID Professional Scientific Technical Support Services (PSTSS) Contract. She previously worked as a Confirmation Scientist for a clinical drug testing company formerly known as Burlington Labs (now Aspenti Health) and served as an Adjunct Faculty Instructor for Champlain College in Burlington, Vermont. Erin received her Cellular and Integrative Physiology from the University of Nebraska Medical Center and her Bachelor of Science in Biotechnology from the University of Nebraska Omaha.


Front Page: